Educational information only — not medical advice. Most peptides here are not FDA-approved.

Compare peptides

Choose two or three to see them side by side. Everything comes from each peptide’s own page.

Peptide 1

Peptide 2

Peptide 3 (optional)

Compare	CJC-1295 (no DAC) + Ipamorelin The classic GH-stimulating pair in one vial.	Tesamorelin The only FDA-approved GHRH analog — proven against belly fat.
Category	Growth Hormone Axis	Growth Hormone Axis
Evidence	3/5Each component studied in humans for GH release; the combined long-term outcomes data is thin.	5/5Phase 3 RCTs in HIV lipodystrophy led to FDA approval; off-label populations less studied.
FDA status	Not FDA-approved	FDA-approved (Egrifta, 2010)
WADA (sport)	Banned	Banned
Also known as	Modified GRF 1-29 + Ipamorelin, CJC/Ipa blend	Egrifta, TH9507
How it works	Two receptors, one pulse: GHRH-receptor stimulation (CJC-1295) plus ghrelin-receptor stimulation (ipamorelin) produces a larger-than-either GH release. Short half-life keeps the pulsatile pattern.	Stimulates pituitary GH release through the GHRH receptor, raising IGF-1 and reducing visceral adipose tissue while preserving the natural pulse pattern.
Half-life	CJC no-DAC ≈ 30 min; ipamorelin ≈ 2 h	About 25–40 minutes
Commonly reported doses	Standard (per peptide): 100 mcg, 1–3× daily Conservative: 100 mcg, 5 days on / 2 off, once daily at bedtime	Label dose (Egrifta SV): 2 mg, once daily Community low-dose: 1 mg, once daily, bedtime
Route	Subcutaneous	Subcutaneous, abdomen
Good once mixed	~21 days in the fridge	~14 days in the fridge
Top side effects	Flushing or head rush Water retention Tingling or numb hands	Joint pain Swelling of hands/feet Injection-site reactions
Lowest price per mg	$3.60 (10 mg vial, 40% off)	$4.20 (10 mg vial, 40% off)
Latest lab purity	99.50% (lot CIP0002)	99.61% (lot TES0003)
	Full page Shop ↗	Full page Shop ↗

Popular comparisons